HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
2019 · JNCI Journal of the National Cancer Institute · 164 citations
https://doi.org/10.1093/jnci/djz042
G
Gaia Griguolo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
286
Papers
3.4K
Citations
33
h-index
65
i10-index
Gaia Griguolo is an academic researcher from University of Padua. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies. The author has an h-index of 33, co-authored 244 publications.
ORCID: 0000-0002-8782-4509Papers by this author
worksDevelopment and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
2022 · EBioMedicine · 136 citations
https://doi.org/10.1016/j.ebiom.2021.103801
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
2019 · Journal for ImmunoTherapy of Cancer · 121 citations
https://doi.org/10.1186/s40425-019-0548-6
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
2020 · Nature Communications · 117 citations
https://doi.org/10.1038/s41467-019-14111-3
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
2022 · npj Breast Cancer · 93 citations
https://doi.org/10.1038/s41523-022-00434-w
Immune characterization of breast cancer metastases: prognostic implications
2018 · Breast Cancer Research · 87 citations
https://doi.org/10.1186/s13058-018-1003-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat